Therapeutic proteins, including monoclonal antibodies, have transformed the treatment of many diseases, but their development is often challenged by immunogenicity. This unwanted immune response may lead to infusion reactions, cytokine release syndrome, or the formation of anti-drug antibodies (ADAs). ADAs are a major concern because they can neutralize therapeutic activity by blocking the drug's active site or reduce efficacy indirectly by accelerating drug clearance. Therefore, understanding and managing immunogenicity is essential for ensuring the safety and success of biologic drug development.
ADA formation is a multi-step immune process involving both innate and adaptive immunity. After systemic administration, biologic drugs can be taken up by antigen-presenting cells such as dendritic cells, where they are processed into peptide fragments. These fragments are then presented on MHC-II molecules and recognized by CD4+ helper T cells through T-cell receptors. Activated helper T cells subsequently stimulate specific B cells to differentiate into plasma cells and produce ADAs. Early ADAs are often low-affinity IgM antibodies, but class-switching and affinity maturation can generate higher-affinity IgG, IgE, or IgA antibodies, resulting in a stronger and more persistent immune response.
The risk of ADA development is influenced by product-, patient-, and disease-related factors, with product-related risks being especially important for drug developers. Molecular characteristics such as non-human amino acid sequences in chimeric antibodies or fusion proteins can increase immunogenicity. Formulation factors, including impurities, aggregates, and certain excipients, may also enhance immune activation. Dose, dosing frequency, target, and mechanism of action further shape immunogenicity risk; for example, drugs that target immune cells or are designed to stimulate immune responses generally carry a higher intrinsic risk.
ADAs can significantly affect a biologic drug's pharmacokinetics and ADME profile. In bioanalysis, ADA formation creates both free drug and immune complex-bound drug, making it important to clarify whether an assay measures free drug, total drug, or both. For large biologics such as monoclonal antibodies, ADAs usually accelerate clearance because immune complexes are rapidly removed by phagocytic cells in the liver and spleen, reducing drug exposure and efficacy. In contrast, for smaller protein drugs normally cleared through the kidneys, ADA binding may increase molecular size, reduce renal filtration, and prolong circulation time. ADA formation may also alter tissue distribution by limiting tissue penetration and increasing liver accumulation.
Immunogenicity assessment commonly uses a tiered ADA testing strategy, beginning with a sensitive screening assay, followed by a confirmatory assay to verify specificity, and characterization assays to determine ADA titer and neutralizing activity. Beyond detecting ADAs after they appear, proactive immunomodulatory assessment can help predict immune-related risks earlier in development. The T-cell-dependent antibody response (TDAR) assay, often using keyhole limpet hemocyanin as a model antigen, evaluates the immune response from antigen presentation to T-cell help, B-cell activation, and antibody production. Overall, effective ADA assessment requires both robust analytical methods and a strong understanding of immunology to support safer and more reliable biologic drug development.
Contact us today to learn how Prisys Biotech can support your immunogenicity assessment strategy and accelerate your biologic drug development program.
